Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 6/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 3/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153421 | 0.84 | AURKA (0.45) | RPS6KB1AURKASIRT2P2RX7SYK | |
| SCHEMBL6156769 | 0.83 | ROCK2 (0.47) | RPS6KB1AURKASIRT2P2RX7SYK | |
| SCHEMBL6155049 | 0.83 | FLT3 (0.44) | RPS6KB1AURKASIRT2P2RX7SYK | |
| SCHEMBL6154975 | 0.80 | RPS6KB1 (0.42) | RPS6KB1AURKASIRT2P2RX7SYK | |
| SCHEMBL6153679 | 0.80 | HTR4 (0.48) | RPS6KB1AURKASIRT2P2RX7SYK | |
| SCHEMBL6153310 | 0.77 | EPHX1 (0.48) | RPS6KB1AURKASIRT2P2RX7SYK | |
| SCHEMBL6154413 | 0.77 | IRAK4 (0.48) | — | |
| SCHEMBL6153513 | 0.77 | SYK (0.46) | RPS6KB1AURKASIRT2P2RX7SYK | |
| SCHEMBL6154140 | 0.76 | HTR4 (0.45) | RPS6KB1SYKFLT3MAPK1 | |
| Trifluoroacetic Acid SCHEMBL6156921 | 0.76 | CACNA1B (0.45) | RPS6KB1AURKASIRT2P2RX7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | RPS6KB1 1050/4885AURKA 2136/4885SIRT2 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.